文献速递肺外科

美国胸科医师学会定义的中危肺癌手术患者并发症与死亡率:ESTS数据库分析

Morbidity and mortality of lung resection candidates defined by the American College of Chest Physicians as 'moderate risk': an analysis from the European Society of Thoracic Surgeons database.
PubMed 文献 · Eur J Cardiothorac Surg · 2021-01-01

基于欧洲胸外科医师学会(ESTS)数据库2007—2019年数据,纳入2016例被美国胸科医师学会指南定义为中危的解剖性肺癌切除术患者,评估其心肺并发症与30天死亡率。结果显示不同术式并发症发生率21%—29%,30天死亡率3.4%—8.9%,且VO2max 10—15 ml/kg/min者死亡率更高。

要点

  • 中危患者肺切除术后并发症与死亡率不可忽视,需充分术前讨论与知情决策。
  • 肺叶切除30天死亡率3.4%,全肺切除7.8%,双肺叶切除8.9%。
  • VO2max 10—15 ml/kg/min与较高死亡率相关,开放手术下差异更明显。

核心结论

  • 中危患者肺切除术后并发症和死亡率不可忽视,支持术前充分讨论与知情决策。
  • 在中危组内,VO2max<15 ml/kg/min与更高死亡率独立相关。

研究设计与样本

  • 基于ESTS数据库2007—2019年解剖性肺癌切除术患者的回顾性分析。
  • 共纳入2016例被美国胸科医师学会指南定义为中危的患者。
  • 按手术类型评估心肺并发症和30天死亡率。

主要发现

  • 心肺并发症发生率:肺叶切除21%(294/1435)、双肺叶切除29%(33/112)、全肺切除22%(72/333)、肺段切除16%(22/136),方差分析P=0.07。
  • 30天死亡率:肺叶切除3.4%(49/1435)、双肺叶切除8.9%(10/112)、全肺切除7.8%(26/333)、肺段切除3.7%(5/136),方差分析P=0.0005。
  • VO2max 10—15 ml/kg/min者30天死亡率5.7%(49/861),高于VO2max更高者的3.5%(41/1155),P=0.022。
  • 微创非全肺切除手术中,VO2max 10—15与更高者死亡率无差异[3.8%(7/181)vs 4.0%(11/272),P=0.92]。
  • 开放手术中,VO2max 10—15者死亡率高于更高者[5.1%(26/501)vs 2.8%(20/721),P=0.034]。

关键数值与推荐

  • 中危定义:预测术后FEV1或预测术后DLCO<60%,且VO2max 10—20 ml/kg/min。
  • VO2max 10—15 ml/kg/min者30天死亡率较更高VO2max者高1.6倍[5.7%(49/861)vs 3.5%(41/1155),P=0.022]。

临床怎么用

  • 对中危患者应个体化评估手术风险,充分告知并发症与死亡风险。
  • VO2max 10—15 ml/kg/min者优先考虑微创手术以降低死亡风险。
  • 开放手术下VO2max 10—15 ml/kg/min者风险更高,需谨慎决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The American College of Chest Physicians functional guidelines classify patients with predicted postoperative forced expiratory volume in 1 s or predicted postoperative carbon monoxide lung diffusion capacity <60% and with maximal oxygen consumption (VO2max) between 10 and 20 ml/kg/min in a heterogeneous category broadly defined as 'moderate risk' with variable morbidity and mortality. Data to support this statement are lacking. Using the European Society of Thoracic Surgeons database, our goal was to test this definition by evaluating the morbidity and mortality of those patients falling into this class. METHODS: All patients who had anatomical lung resection for lung cancer (2007-2019) and were deemed of moderate risk were identified in the European Society of Thoracic Surgeons database. Cardiopulmonary morbidity and 30-day mortality of these patients were assessed by the type of operation. RESULTS: A total 2016 patients were identified. The incidence of cardiopulmonary complications in this group was 21% after lobectomy (294/1435), 29% after bilobectomy (33/112), 22% after pneumonectomy (72/333) and 16% after segmentectomy (22/136) (analysis of variance P = 0.07). The 30-day mortality was 3.4% after lobectomy (49/1435), 8.9% after bilobectomy (10/112), 7.8% after pneumonectomy (26/333) and 3.7% after segmentectomy (5/136) (analysis of variance P = 0.0005). The 30-day mortality rate was 1.6-fold higher in patients with a VO2max between 10 and 15 ml/kg/min compared to those with a higher VO2max [49/861 (5.7%) vs 41/1155 (3.5%); P = 0.022]. For operations that were less extensive than a pneumonectomy and were performed by minimally invasive surgery, there was no difference in mortality between patients with a VO2max between 10 and 15 ml/kg/min and those with a higher VO2max [7/181 (3.8%) vs 11/272 (4.0%); P = 0.92]. On the other hand, after open surgery, the mortality of patients with a lower VO2max (10-15 ml/kg/min) was higher than that of those with a higher VO2max [26/501 (5.1%) vs 20/721 (2.8%); P = 0.034]. Linear regression adjusting for the extent and access of the operation confirmed that within the moderate-risk group a VO2max <15 ml/kg/min was associated with higher mortality (P = 0.028; odds ratio 1.61; 95% confidence interval 1.1-2.5). CONCLUSIONS: Morbidity and mortality rates found in this study are not negligible and reinforce the recommendation to ensure careful patient discussion and informed decision-making prior to lung cancer resection surgery.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Gooseman MR, Falcoz PE, Decaluwe H, et al. Morbidity and mortality of lung resection candidates defined by the American College of Chest Physicians as 'moderate risk': an analysis from the European Society of Thoracic Surgeons database. Eur J Cardiothorac Surg. 2021. PMID: 33760020. doi:10.1093/ejcts/ezab028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。